Skip to main content
EJNMMI Radiopharmacy and Chemistry
Fig. 2 | EJNMMI Radiopharmacy and Chemistry

Fig. 2

From: [225Ac]Ac- and [111In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts

Fig. 2

Binding of [111In]In-DOTA-trastuzumab to HER2-positive SK-BR-3 human BC cells in the absence (TB) or presence (NSB) of a 50-fold molar excess of trastuzumab. The SB was calculated by subtracting NSB from TB. Fitting the SB curve to a 1-site receptor binding model estimated the KD = 1.2 ± 0.3 × 10–8 mol/L and Bmax = 4.2 ± 0.2 × 106 receptors/cell

Back to article page